共查询到20条相似文献,搜索用时 0 毫秒
1.
Comparative evaluation of methods approximating drug prescription durations in claims data: modeling,simulation, and application to real data
下载免费PDF全文
![点击此处可从《Pharmacoepidemiology and drug safety》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Andreas D. Meid Dirk Heider Jürgen‐Bernhard Adler Renate Quinzler Herrmann Brenner Christian Günster Hans‐Helmut König Walter E. Haefeli 《Pharmacoepidemiology and drug safety》2016,25(12):1434-1442
2.
3.
4.
5.
J. P. Ottervanger H. A. Valkenburg D. E. Grobbee B. H. C. Stricker 《European journal of clinical pharmacology》1996,50(5):353-355
Objective:
To investigate the frequency of use and misuse of sumatriptan, and to explore the characteristics of patients reporting overuse.
Setting:
A postmarketing cohort study on adverse reactions to sumatriptan, performed with the assistance of drug-dispensing general
practitioners in the Netherlands.
Methods:
Questionnaires were sent to patients on sumatriptan of drug-dispensing general practitioners in the Netherlands. Use of sumatriptan
was classified into five groups: < 1, 1–10, 11–20 and 21–30 times per month and a group of patients who reported daily use
of sumatriptan more than 10 times per week. Patients in the latter group were regarded as “overusers”.
Results:
The request to the 1720 patients yielded a response rate of 1202 (70%). Of 952 (79%) of these patients, details of their sumatriptan
intake were available. Most patients (718, 75%) took sumatriptan 1–10 times each month. However, 36 patients (4%, 95% CI 2.8–5.2%)
took sumatriptan daily or more than 10 times each week. The group with the highest intake consisted mainly of males, and many
patients who reported a poor efficacy of sumatriptan. Age was not related to use of sumatriptan.
Conclusions:
A small group of patients (4%) used sumatriptan too often. A high intake was associated with both male gender and a reported
poor efficacy of sumatriptan, but not with age, reported adverse reactions, or headache attributed to sumatriptan. It is important
to explain to patients that sumatriptan is only for the treatment of acute attacks, and not for prophylactic use. Drug consumption
patterns have to be evaluated, in particular in patients who report low efficacy of sumatriptan.
Received: 24 July 1995/Accepted in revised form: 5 October 1995 相似文献
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.